X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BA-210 (cethrin) is a first-in-class, topically applied, biologic Rho inhibitor, developed BA-210 to inactivate Rho and has brought the compound forward to clinical testing. BA-210 has both orphan drug status and Fast Track designation from the FDA.
Lead Product(s): Cethrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BA-210
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Neurelis intends to submit an Investigational New Drug (IND) application with the FDA on BioAxone's lead compound, BA-1049, in 2022. BioAxone's lead product, BA-1049, offers an opportunity to treat CCMs by stabilizing lesions and by preventing new lesions from emerging.
Lead Product(s): BA-1049
Therapeutic Area: Neurology Product Name: BA-1049
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurelis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 21, 2021
Details:
The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.
Lead Product(s): BA-1049
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BA-1049
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
